US7602731025 - Common Stock
REPARE THERAPEUTICS INC
NASDAQ:RPTX (11/4/2024, 8:00:02 PM)
After market: 3.62 +0.04 (+1.12%)3.58
0 (0%)
Repare Therapeutics, Inc. engages in the research, development, and commercialization of precision oncology drugs targeting specific vulnerabilities of tumors in genetically defined patient populations. The company is headquartered in St-Laurent, Quebec and currently employs 179 full-time employees. The company went IPO on 2020-06-19. The firm is engaged in the proprietary SL approach to the discovery and development of novel therapeutics. The company uses its genome-wide, CRISPR-enabled SNIPRx platform to systematically discover and develop cancer therapies focused on genomic instability, including deoxyribonucleic acid (DNA) damage repair. The Company’s initial product candidate, camonsertib (RP-3500 or RG6526), a potent and selective oral small molecule inhibitor of Ataxia-Telangiectasia and Rad3-related protein kinase (ATR) for the treatment of solid tumors with specific DNA damage repair-related genomic alterations, including those in the ataxia telangiectasia mutated kinase (ATM) gene as part of a network of 16 STEP2-identified genomic alterations. Its other pipeline includes Lunresertib PKMYT1 Inhibitor and RP-3467 polymerase theta (Pol0) Inhibitor.
REPARE THERAPEUTICS INC
7210 Frederick-Banting, Suite 100
ST-LAURENT QUEBEC H4S 2A1
P: 18574127018
CEO: Lloyd M. Segal
Employees: 179
Website: https://www.reparerx.com/
Here you can normally see the latest stock twits on RPTX, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits: